Sonnenborn, U. Escherichia coli strain Nissle 1917-from bench to bedside and back: history of a special Escherichia coli strain with probiotic properties. FEMS Microbiol. Lett. 363 , 1–6 (2016).
In the quest for mitigators of bacterial virulence, cell-free supernatants (CFS) from 25 human commensal and associated bacteria were tested for activity against Pseudomonas aeruginosa. Among these, Escherichia coli Nissle 1917 CFS significantly inhibited biofilm formation and dispersed extant pseudomonas biofilms without inhibiting planktonic bacterial growth. eDNA was reduced in biofilms
The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis. 2018 Dec;97 (51):e13792. doi: 10.1097/MD.0000000000013792. As the exact pathogenesis of inflammatory bowel disease (IBD) is not known, there is increasing evidence of clinical trials and animal models that indicate the beneficial effects of probiotics.
Background: Probiotic Escherichia coli Nissle 1917 (EcN) has been widely studied for the treatment of intestinal inflammatory diseases and infectious diarrhea, but the mechanisms by which they communicate with the host are not well-known. Outer membrane vesicles (OMVs) are produced by Gram-negative bacteria and deliver microbial molecules to
To assess the impact of the intestinal microbiota on protection of mice with severely compromised adaptive immunity from bacterial translocation, we challenged GF- or SPF-raised Rag1 −/− mice orally with E. coli strain Nissle 1917, a probiotic E. coli strain used to treat IBD and other intestinal diseases , or with E. coli mpk, a commensal
Alvarez, C.-S., Badia, J., Bosch, M., Giménez, R., and Baldomà, L. (2016). Outer membrane vesicles and soluble factors released by probiotic Escherichia coli Nissle 1917 and commensal ECOR63 enhance barrier function by regulating expression of tight junction proteins in intestinal epithelial cells. Front.
. 895 13 690 214 404 387 213 943
escherichia coli nissle 1917 probiotic
